Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined oral thiamine and biotin therapy in Huntington's disease
2023-508637-14-00Phase 2Authorised
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Jun 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thiamine and biotin in Huntington disease (HD), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoints: Clinical safety assessment, Adverse event collection and 1 more. Planned start Jun 2024; status: authorised.
02
Drugs
thiaminebiotin
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2023-508637-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508637-14-00.